Stockscreener 앱 받기
1.04
5.48%
0.054
시간 외 거래:
1.03
-0.01
-0.96%
전일 마감가:
$0.986
열려 있는:
$0.9606
하루 거래량:
1.76M
Relative Volume:
0.54
시가총액:
$107.53M
수익:
$65,300
순이익/손실:
$-84.93M
주가수익비율:
-0.6089
EPS:
-1.708
순현금흐름:
$-83.57M
1주 성능:
-4.59%
1개월 성능:
-10.34%
6개월 성능:
-12.61%
1년 성능:
-59.06%
1일 변동 폭
$0.9606
$1.06
1주일 범위
$0.95
$1.18
52주 변동 폭
$0.5632
$2.72
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.04 | 107.53M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Price to sales ratio of Inovio Pharmaceuticals, Inc. – HAN:GBM - TradingView
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals (INO) Short Interest & Short Float | Updated Oct 2026 $INO - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer - Zacks Investment Research
Inovio Pharmaceuticals (INO) Institutional Ownership 2026 $INO - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Updates Bylaws with New Exclusive-Forum Provision - The Globe and Mail
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio advances FDA review: Inovio Pharmaceuticals stock falls 3.77 percent - AD HOC NEWS
Inovio Pharmaceuticals stock fell 4.13 percent before FDA decision - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals stock approaches its October FDA test - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Debt to equity ratio of Inovio Pharmaceuticals, Inc. – HAN:GBM - TradingView
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals stock trades lower as FDA date nears - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as price crosses 200-day moving average - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view - AD HOC NEWS
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com South Africa
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com Nigeria
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - TradingView
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - Yahoo Finance
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com India
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - TradingView
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - Yahoo Finance
INOVIO at Cantor Fitzgerald healthcare conference: FDA decision nears By Investing.com - Investing.com India
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO Steps Up Investor Outreach at New York Conferences - MyChesCo
INO Stockholders Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INOVIO to Participate in Upcoming Investor Conferences - Eastern Progress
Inovio Pharmaceuticals Stock Price Forecast. Should You Buy INO? - StockInvest.us
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as analysts see sharp upside - ad-hoc-news.de
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Investor talks begin Sept. 9 as INOVIO joins two conferences - Stock Titan
INOVIO to Participate in Upcoming Investor Conferences - PR Newswire
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.35%
자본화:
|
볼륨(24시간):